NEW YORK, August 6, 2026, 11:04 EDT
- Iovance stock climbed 39.2% to $6.04 in morning trade on the Nasdaq.
- Second-quarter revenue totalled $99.3 million, exceeding the upper end of guidance by 12.9%.
- The previous full-year upper range now calls for an almost unchanged quarterly run rate.
Iovance Biotherapeutics, Inc. NASDAQ:IOVA climbed 39.2% early Thursday after the company posted record revenue for its second quarter. Shares changed hands at $6.04 as of 10:49 a.m. EDT, having previously reached a new 52-week peak of $6.385.
By midday, trading volume had climbed to 31.2 million shares, more than doubling the 65-day daily average of 15.3 million.
Gross profit emerged as the key indicator for investors, surpassing top-line sales. Gross profit climbed to roughly $55.7 million, compared to $11.1 million the previous year. Revenue advanced 66%, while disclosed cost of sales decreased by 11%.
The fivefold jump in gross profit indicates Iovance is achieving significant manufacturing leverage. The company’s centralized production network was known for its previously high fixed costs.
Iovance reported product revenue of $99.3 million for the second quarter, surpassing its forecast of $86 million to $88 million. U.S. Amtagvi sales reached approximately $91 million, exceeding the projected range of $79 million to $81 million.
| Q2 2026 scorecard | Actual | Previous reference | Difference |
|---|---|---|---|
| Total product revenue | $99.3 million | Company guide: $86 million-$88 million | 12.9% above top end |
| U.S. Amtagvi revenue | About $91 million | Company guide: $79 million-$81 million | Roughly 12.3% higher than top end |
| GAAP loss per share | $0.11 | FactSet estimate: $0.13 | $0.02 improvement |
| Gross margin | 56% | Q1 2026: 41% | Up about 15 percentage points |
Depreciation and amortization not included. Source: Iovance regulatory filings and FactSet statistics as reported by the Wall Street Journal.
The quarter also alters the annual calculation. Product revenue in the first half totaled $170.7 million. As a result, Iovance’s projected range of $350 million to $370 million for the year means it needs to generate between $179.3 million and $199.3 million in the second half.
| 2026 target as stated | Required H2 revenue | Average needed each remaining quarter | Compared to Q2 run rate |
|---|---|---|---|
| $350 million, lowest | $179.3 million | $89.6 million | 9.8% less |
| $360 million, midpoint | $189.3 million | $94.6 million | 4.7% less |
| $370 million, highest | $199.3 million | $99.6 million | 0.3% more |
Figures reflect reporter analysis using Iovance’s unverified first-half sales and current company projections.
The upper range now needs performance similar to Q2, while the midpoint would permit revenue to fall by nearly 5% from the previous quarter.
Interim CEO Frederick Vogt stated that U.S. Amtagvi demand was the main driver for the quarter. Vogt noted that Iovance is “reviewing our previously issued 2026 revenue guidance.” The company expects to provide an update in the third quarter. Securities and Exchange Commission
Margins increased at a quicker pace than sales. Management also reported that R&D expenditures declined for the fourth straight quarter.
| Operating measure | Q2 2025 | Q1 2026 | Q2 2026 | Year-on-year change |
|---|---|---|---|---|
| Product revenue | $60.0 million | $71.4 million | $99.3 million | up 65.7% |
| Calculated gross profit | $11.1 million | $28.9 million | $55.7 million | jumped 403.3% |
| Calculated gross margin | 18.5% | 40.5% | 56.1% | rose by 37.6 points |
| Net loss | $111.7 million | $79.0 million | $47.3 million | decreased 57.6% |
| R&D expense | $77.9 million | $62.5 million | $58.9 million | fell 24.5% |
| Weighted-average shares | 334.5 million | 418.5 million | 450.2 million | increased 34.6% |
*Revenue minus cost of sales, not including depreciation and amortization. Numbers are unaudited.
Dilution continues to offset gains. Weighted-average shares increased almost 35% compared to a year ago. This rise constrains the amount of value available to each current share.
As of June 30, cash, investments, and restricted cash stood at approximately $304 million, down from around $319 million at the end of the previous quarter. The company’s management anticipates that existing resources will be sufficient to support operations through the second half of 2028.
Commercial performance strengthened. Iovance has expanded to over 95 authorized treatment centers in the United States, Canada, and Australia. The company aims to reach at least 110 centers by the end of the year. Manufacturing turnaround times have decreased to 31 days or below.
Pipeline catalysts continue to be significant. Enrollment in the pivotal lung-cancer cohorts is almost complete, with an update anticipated in the fourth quarter. Iovance intends to submit a supplemental application in 2027. The firm also secured FDA Fast Track designation for two forms of soft-tissue sarcoma. Early findings indicated responses in three out of the first six evaluable patients.
All recent analyst actions were released before Thursday’s results.
| Firm | Analyst | Recommendation | Price target | Latest action |
|---|---|---|---|---|
| Chardan Capital | Geulah Livshits | Buy | $14 | Reduced from $16 on May 7 |
| UBS | David Dai | Neutral | $4 | Increased from $2 on March 5 |
| Citizens | Reni J. Benjamin | Market Outperform | $5 | Upgrade as of March 3 |
| Barclays | Etzer Darout | Overweight | $11 | Lifted from $10 on February 25 |
Among nine analysts tracked by FactSet, six rate the stock as Buy, one assigns Overweight, and two suggest Hold. There are no Underweight or Sell ratings. The median price target stands at $9, with estimates spanning $4 to $14.
The median price target of $6.04 suggests an increase of roughly 49%. Meanwhile, the lowest target indicates a potential decline of 34%. The significant gap highlights ongoing uncertainty about recurring demand and future profit margins.
Risks: Amtagvi is still the leading source of revenue. Interruptions in production, constraints on reimbursement, or a slower pace of referrals might impact expansion. The ongoing review of guidance has not formally raised forecasts yet. Early data from limited patient groups may shift as additional individuals receive treatment. Ongoing share sales may further dilute existing investors.
Thursday’s rally reflects expectations of consistent performance. The focus now shifts to whether Iovance will increase its guidance and maintain revenue at the Q2 rate. A softer third quarter could undermine the argument for improved operating leverage.
Related articles: NASDAQ:IOVA
